Exec advised hip recall months before J&J acted; Shire pays $48M to settle Adderall XR case;

@FiercePharma: Daiichi sales reps sue for discrimination. $100M damages sought. Same law firm that handled Novartis case. Story | Follow @FiercePharma

@EricPFierce: Merck to whittle away further at its manufacturing network. More | Follow @EricPFierce

@AlisonBFierce: Feds nail supplier of unapproved cancer drugs. This after authorities found counterfeit Altuzan making the rounds. News | Follow @AlisonBFierce

> A top marketing executive at Johnson & Johnson's ($JNJ) DePuy unit flagged safety problems in the ASR hip replacement device and suggested a recall almost a year before the company pulled the product, according to testimony in a product liability suit. Report

> Shire ($SHPG) paid Impax Laboratories ($IPXL) $48 million to settle a legal battle over Shire's agreement to supply an authorized generic version of the ADHD drug Adderall XR. Report

> Once again, drugmakers stand among the list of companies forced to pay up as the U.S. government prosecutes Medicare and Medicaid fraud. Report

> U.S.-based Perrigo ($PRGO) expanded its presence in the U.K. with a £180 million ($281.8 million) buyout of Rosemont, a privately held company that makes liquid versions of drugs. Report

Medical Device News

 @FierceMedDev: Biodegradable plastics + stem cells rebuild broken bone. Item | Follow @FierceMedDev

 @MarkHFierce: U.K. researchers developed a stem/cell device hybrid device that repairs broken bones and then biodegrades. Release | Follow @MarkHFierce

 @DamianFierce: Endo's likely headed for a sale, and some analysts say device giant Covidien would be a perfect match. Report | Follow @DamianFierce

> Swiss stent developer grabs $4.3M series B in crowded EU market. Story

> Stimatix looks for partner, buyer as it eyes stoma market. News

> Nanomix rolls out U.S. trial for heart attack blood Dx. Article

Biotech News

 @FierceBiotech: New special report: 25 most influential people in biopharma today. Report | Last year's list: More | Follow @FierceBiotech

@JohnCFierce: StemCells is jumping on very early, positive results from tiny spinal cord study. Release | Follow @JohnCFierce

@RyanMFierce: Burrill backed India-based outfit with diagnostics biz ambitions. Burrill & Co. landed $505M for latest VC fund. News | Follow @RyanMFierce

> Analysts urge AstraZeneca's Soriot to think big on M&A front. Story

> Merck ups autoimmune prize to $600M for small Michigan biotech. More

> StemCells soars after spinal trial gains persist in 2 patients. Item

Biotech Research News

> Stem cell discovery could drive new bone repair therapies. Article

> Acorda drug boosts motor functions in rats after stroke. Report

> Compound preserves heart cells, tissue after heart attack or stroke damage. Story

> Dogs with diabetes 'cured' with gene therapy. Item

Pharma Manufacturing News

> Kazakhstan government plans to build biologics plant. Article

> Japan's Eisai sells Taiwan plant in revamp of manufacturing. Story

> Feds nail supplier of unapproved cancer drugs. News

> More Merck manufacturing cuts on the way. Report

And Finally... Researchers found scads of antibiotic-resistance genes in manure-fertilized soil near Chinese pig farms. Report

Suggested Articles

After global recalls of heartburn medicine Zantac and an FDA ban, the Department of Justice is investigating Sanofi and GlaxoSmithKline.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.